- Home
- SIM vs BLTE Comparison
SIM vs BLTE Comparison
Compare SIM & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIM | BLTE |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.1B |
| IPO Year | 1993 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SIM | BLTE |
|---|---|---|
| Price | $29.15 | $154.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $149.00 |
| AVG Volume (30 Days) | 1.8K | ★ 326.1K |
| Earning Date | 10-27-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $1,698,258,820.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.15 | $49.00 |
| 52 Week High | $34.59 | $162.00 |
Technical Indicators
Market Signals| Indicator | SIM | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | 66.03 |
| Support Level | $26.00 | $141.00 |
| Resistance Level | $29.70 | $158.50 |
| Average True Range (ATR) | 1.69 | 7.53 |
| MACD | -0.16 | -0.86 |
| Stochastic Oscillator | 36.67 | 67.51 |
Price Performance
Historical ComparisonAbout SIM Grupo Simec S.A.B. de C.V.
Grupo Simec SAB de CV is a diversified producer, processor and distributor of SBQ steel and structural steel products with production and commercial operations. The group's SBQ products are used across a range of engineered end-user applications, including axles, hubs, and crankshafts for automobiles and light trucks, machine tools, and off-highway equipment. Its structural steel products are used in the non-residential construction market and other construction applications. Its segments are Mexico, Brazil, and the United States. The maximum of its sales is from the Mexico segment.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.